公开(公告)号：US20240360223A1

公开(公告)日：2024-10-31

申请号：US18622766

申请日：2024-03-29

Applicant: Dragonfly Therapeutics, Inc.

Inventor： Aaron BELLI ,  Ann F. CHEUNG ,  Stacey V. DRABIC ,  Daniel FALLON ,  Benjamin FISCHER ,  Asya GRINBERG ,  Pyae P. HEIN ,  Alexander IVANOV ,  Zong Sean JUO ,  Mark LEWANDOWSKI ,  Xinbi LI ,  Matthew SCHNEIDER

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2851 ,  C07K16/283 ,  C07K16/2878 ,  A61K39/00 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76

Abstract: Multispecific binding proteins that bind NKG2D receptor, CD16, and B cell-activating factor receptor (BAFF-R) are described, as well as pharmaceutical compositions and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer and autoimmune inflammatory diseases.

公开(公告)号：US12129309B2

公开(公告)日：2024-10-29

申请号：US17736475

申请日：2022-05-04

Applicant: Xencor, Inc.

Inventor： Matthew Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal

IPC: C07K16/40 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/40 ,  C07K16/18 ,  C07K16/2809 ,  C07K16/2896 ,  C07K16/3061 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

公开(公告)号：US12128018B2

公开(公告)日：2024-10-29

申请号：US16246320

申请日：2019-01-11

Applicant: KDAc Therapeutics, Inc.

Inventor： Edward Holson ,  Mariana Nacht

IPC: A01N43/00 ,  A01N43/46 ,  A61K31/167 ,  A61K31/403 ,  A61K31/415 ,  A61K31/55 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K31/167 ,  A61K31/403 ,  A61K31/415 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/545 ,  C07K2317/73 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/403 ,  A61K2300/00 ,  A61K31/415 ,  A61K2300/00 ,  A61K39/3955 ,  A61K2300/00

Abstract: Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histone deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).

公开(公告)号：US20240352140A1

公开(公告)日：2024-10-24

申请号：US18439951

申请日：2024-02-13

Applicant: Janssen Biotech, Inc.

Inventor： Homer Adams, III ,  Arnob Banerjee ,  Suzette Girgis ,  Jenna Goldberg ,  Tara Stephenson ,  Raluca Verona ,  Shun xin Wang lin

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/46

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76

Abstract: Methods of treating cancers using a BCMA×CD3 bispecific antibody arc described.

公开(公告)号：US20240350624A1

公开(公告)日：2024-10-24

申请号：US18428597

申请日：2024-01-31

Applicant: Duke University ,  The Government of the United States as represented by the Secretary of Health

Inventor： Darell Bigner ,  Vidyalakshmi Chandramohan ,  Smita Nair ,  Matthias Gromeier ,  Xuhui Bao ,  Ira H. Pastan

IPC: A61K39/395 ,  A61K38/16 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/395 ,  A61K38/164 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6851 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/55

Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.

公开(公告)号：US20240343823A1

公开(公告)日：2024-10-17

申请号：US18432750

申请日：2024-02-05

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Daniel Janssen ,  Carlo Boutton ,  Evelyne Dombrecht ,  Bram Laukens ,  Paolo Meoni ,  Lily Pao ,  Jan Pype ,  Peter Schotte ,  Benedikte Serruys ,  Ana Paula Vintem ,  Diane Van Hoorick

IPC: C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/303 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/30

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

公开(公告)号：US12116406B2

公开(公告)日：2024-10-15

申请号：US16617445

申请日：2018-05-25

Applicant: Fred Hutchinson Cancer Center

Inventor： Roland B. Walter ,  Christopher Mehlin ,  George S. Laszlo ,  Colin E. Correnti

IPC: C07K16/30 ,  A61P35/02 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/2803 ,  A61P35/02 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/92

Abstract: Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes FIG. 1A on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33ΔE2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33ΔE2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets can increase therapeutic efficacy against CD-33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.

公开(公告)号：US12103977B2

公开(公告)日：2024-10-01

申请号：US17702282

申请日：2022-03-23

Applicant: Janssen Biotech, Inc.

Inventor： Rajkumar Ganesan ,  Anna Kuchnio ,  Cassandra L. Lowenstein ,  Ulrike Philippar ,  Sanjaya Singh ,  Nele Vloemans ,  Danlin Yang

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61P35/00 ,  C07K16/2878 ,  C07K16/2887 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.

公开(公告)号：US20240317852A1

公开(公告)日：2024-09-26

申请号：US18281156

申请日：2022-03-09

Applicant: MOLECULAR PARTNERS AG

Inventor： Nina RESCHKE ,  Christian REICHEN ,  Bernd SCHLERETH

IPC: C07K16/28 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2809 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/31

Abstract: The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for human CD33, in addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g., acute myeloid leukemia (AML), in mammal, including a human.

公开(公告)号：US12098215B2

公开(公告)日：2024-09-24

申请号：US16307621

申请日：2017-06-06

Applicant: NORTHWESTERN UNIVERSITY

Inventor： Milan Mrksich ,  Justin A. Modica

IPC: C07K16/46 ,  A61P19/02 ,  A61P35/00 ,  A61P37/00 ,  C07K16/32 ,  C12N9/18 ,  A61K39/00

CPC classification number: C07K16/46 ,  A61P19/02 ,  A61P35/00 ,  A61P37/00 ,  C07K16/32 ,  C12N9/18 ,  C12Y301/01074 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/61 ,  C12Y201/01037 ,  C12Y301/21002 ,  C12Y302/01021 ,  C12Y304/11018 ,  C12Y304/24024 ,  C12Y305/02006

Abstract: The disclosure provides constructs comprising a first fusion protein, a second fusion protein, and a linker, wherein the first fusion protein and the second fusion protein each include an affinity reagent and a reactive enzyme, and the linker includes a first and second functional groups specific for irreversibly inhibiting the first and second fusion protein reactive enzymes. The disclosure further provides a method including (a) contacting a first fusion protein including an affinity reagent and a reactive enzyme with a linker including a functional group specific for irreversibly inhibiting the first fusion protein reactive enzyme thereby coupling the first fusion protein and the linker, and (b) contacting a second fusion protein including an affinity reagent and a reactive enzyme with the linker, the linker including a functional group specific for irreversibly inhibiting the second fusion protein reactive enzyme thereby coupling the second fusion protein and the linker.